Triple
T11074753
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | CLEOPATRA trial |
E261834
|
entity |
| Predicate | drugEvaluated |
P65948
|
FINISHED |
| Object | docetaxel |
E261833
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: docetaxel | Statement: [CLEOPATRA trial, drugEvaluated, docetaxel]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: docetaxel Context triple: [CLEOPATRA trial, drugEvaluated, docetaxel]
-
A.
docetaxel
chosen
Docetaxel is a chemotherapy drug in the taxane class used to treat various cancers, including breast, lung, prostate, and gastric cancers, by inhibiting cell division.
-
B.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
C.
irinotecan
Irinotecan is a chemotherapy drug, specifically a topoisomerase I inhibitor, commonly used to treat colorectal and other cancers.
-
D.
mitoxantrone
Mitoxantrone is an anthracenedione chemotherapeutic agent used primarily to treat certain cancers and multiple sclerosis by intercalating DNA and inhibiting topoisomerase II.
-
E.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d6aa9983c08190b0ef61603b69feac |
completed | April 8, 2026, 7:20 p.m. |
| NER | Named-entity recognition | batch_69d7994efb608190a81bc8c4d16ddbd0 |
completed | April 9, 2026, 12:19 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69e3c8cc77988190aad54f56dbd0f8cf |
completed | April 18, 2026, 6:09 p.m. |
Created at: April 8, 2026, 9:26 p.m.